Despite spectacular responses seen in some patients with BRCA-deficient breast or ovarian cancers, other patients did not show the expected benefit from PARP inhibitor therapy. Thus, like for all novel tailored anti-cancer drugs, upfront and secondary resistance remain major hurdles in the ...
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tu... Background Veliparib is a potent small molecule inhibitor of PARP-1/2, which is cytotoxic in tumor cells with deficiencies in BRCA1 or ...
Maintenance therapy is given after initial treatment to help prevent cancer from coming back. Avastin is an anti-angiogenic drug that interferes with the development of blood vessels that tumors need to thrive. Lynparza is a PARP inhibitor, which can be lethal to cancer...
correlate with a poor prognosis.102–104 Likewise, amplifications of MDM2 and CCND1 (cyclin D1), although uncommon in GISTs, are associated with malignancy.105 Kinase mutations and tyrosine kinase inhibitor therapy Until the year 2000, treatment options for patients with advanced GIST were poor. ...
Small-cell lung cancer (SCLC) is a deadly cancer associated with smoke exposure that has neuroendocrine (NE) cell properties and is pathologically, molecularly, biologically and clinically very different from other lung cancers. While most patients with SCLC respond initially to cytotoxic therapy, almo...
Other nonselective PDE inhibitor used in the clinical trials is lisofylline. In a small group of septic patients, lisofylline reduced an ARDS-induced increase in the ratio of serum free fatty acids (i.e., the ratio of C18 unsaturated fatty acids linoleate and oleate to fully saturated palmi...
Premature menopause, defined as occurring <40 years of age without iatrogenic causes, is rare and affects approximately 1% of women. Menopausal hormonal therapy (MHT) is often recommended in this population for symptom relief or bone protection, and may contain either unopposed estrogen or combined ...
EnglishEspañolDeutschFrançaisItalianoالعربية中文简体PolskiPortuguêsNederlandsNorskΕλληνικήРусскийTürkçeאנגלית 9 RegisterLog in Sign up with one click: Facebook Twitter Google Share on Facebook ...
Conclusions Early use of PARPis in the therapeutic course of platinum-sensitive ovarian cancer was recommended in the gBRCA mutation cohort. Niraparib is a promising candidate for next front-line maintenance therapy in such patients. Legal entity responsible for the study The author. Funding The ...
Specifically, potential therapeutic protocols utilizing immune checkpoint inhibitors (ICIs), epidermal growth factor receptor inhibitor (EGFRi), poly(ADP-ribose) polymerase inhibitor (PARPi), antibody–drug conjugates (ADCs), oncolytic viruses (OVs), glucose transporter-1 inhibitor (GLUT1i) and ...